Evaluate the Safety, Tolerability and PK of Different Formulations of Orally Administered Solabegron in Healthy Male Subjects
Primary Purpose
Healthy Subjects, Overactive Bladder
Status
Completed
Phase
Phase 1
Locations
Study Type
Interventional
Intervention
Formulation 1 solabegron
Formulation 2 solabegron
Sponsored by
About this trial
This is an interventional treatment trial for Healthy Subjects, Overactive Bladder focused on measuring Overactive bladder, Incontinence
Eligibility Criteria
Inclusion Criteria:
- Body weight greater than or equal to 50 kg, inclusive, and body mass index (BMI) 18.0 - 32.0 kg/m2, inclusive
- In good general health as determined by a thorough medical history and physical examination, ECG, vital signs, and clinical laboratory evaluation. Results of clinical laboratory tests must be without clinically significant abnormalities, including hematology, clinical chemistry and urinalysis.
- Adequate venous access to allow for repeated blood sampling
- Ability to understand and comply with the study requirements
- Provide written informed consent prior to any study procedure being performed (all subjects should be able to understand the informed consent form and any other documents that subjects are required to read).
Exclusion Criteria:
- Any clinically relevant abnormality identified on the screening physical examination, clinical laboratory tests, 12-lead ECG, or any other medical condition or circumstance which would make the subject unsuitable for participation in the study based on the Investigator's assessment
- Resting heart rate greater than or equal to 100 beats per minute (BPM) after 5 minutes rest (as above) at the screening visit
- QTcF interval (Fredericia's correction factor) greater than 450 msec (males subjects) at screening
- History of drug or other allergy, which, in the opinion of the Investigator, contraindicates their participation
- History of smoking, including e-cigarettes, within 3 months of the study and/or a positive urine cotinine at screening
- Regular alcohol consumption averaging ≥ 14 drinks/week for men (1 drink = 5 ounces of wine or 12 ounces of beer or 1.5 ounces of hard liquor) within 6 months of the first dose of study medication.
- Positive urine drug or alcohol test at screening
- Any other condition and/or situation that causes the Investigator to deem a subject unsuitable for the study (e.g., due to expected study medication non-compliance, inability to medically tolerate the study procedures, or a subject's unwillingness to comply with study-related procedures)
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Experimental
Arm Label
Formulation 1 solabegron
Formulation 2 solabegron
Arm Description
Subjects will receive formulation 1 solabegron doses in a single-blind, randomized, cross-over fashion in Periods 1 to 3.
Subjects will receive formulation 2 in a single-blind, randomized, cross-over fashion in Periods 1 to 3.
Outcomes
Primary Outcome Measures
Maximum observed plasma drug concentration (Cmax)
Secondary Outcome Measures
Full Information
NCT ID
NCT02938507
First Posted
October 12, 2016
Last Updated
April 23, 2019
Sponsor
Velicept Therapeutics, Inc.
1. Study Identification
Unique Protocol Identification Number
NCT02938507
Brief Title
Evaluate the Safety, Tolerability and PK of Different Formulations of Orally Administered Solabegron in Healthy Male Subjects
Official Title
A Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Immediate and Modified Release Formulations of Orally Administered Solabegron in Healthy Male Subjects
Study Type
Interventional
2. Study Status
Record Verification Date
April 2019
Overall Recruitment Status
Completed
Study Start Date
October 2016 (undefined)
Primary Completion Date
December 2016 (Actual)
Study Completion Date
December 2016 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Velicept Therapeutics, Inc.
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of different formulations of orally administered solabegron in healthy male subjects.
Detailed Description
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of different formulations of orally administered solabegron in healthy male subjects. Eligible male subjects will be enrolled into 2 cohorts of 12 subjects each conducted in parallel. The study is a single blind (subjects), randomized, cross-over design in 3 study periods.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Healthy Subjects, Overactive Bladder
Keywords
Overactive bladder, Incontinence
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Crossover Assignment
Masking
Participant
Allocation
Randomized
Enrollment
24 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Formulation 1 solabegron
Arm Type
Experimental
Arm Description
Subjects will receive formulation 1 solabegron doses in a single-blind, randomized, cross-over fashion in Periods 1 to 3.
Arm Title
Formulation 2 solabegron
Arm Type
Experimental
Arm Description
Subjects will receive formulation 2 in a single-blind, randomized, cross-over fashion in Periods 1 to 3.
Intervention Type
Drug
Intervention Name(s)
Formulation 1 solabegron
Intervention Type
Drug
Intervention Name(s)
Formulation 2 solabegron
Primary Outcome Measure Information:
Title
Maximum observed plasma drug concentration (Cmax)
Time Frame
24 hours
10. Eligibility
Sex
Male
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Body weight greater than or equal to 50 kg, inclusive, and body mass index (BMI) 18.0 - 32.0 kg/m2, inclusive
In good general health as determined by a thorough medical history and physical examination, ECG, vital signs, and clinical laboratory evaluation. Results of clinical laboratory tests must be without clinically significant abnormalities, including hematology, clinical chemistry and urinalysis.
Adequate venous access to allow for repeated blood sampling
Ability to understand and comply with the study requirements
Provide written informed consent prior to any study procedure being performed (all subjects should be able to understand the informed consent form and any other documents that subjects are required to read).
Exclusion Criteria:
Any clinically relevant abnormality identified on the screening physical examination, clinical laboratory tests, 12-lead ECG, or any other medical condition or circumstance which would make the subject unsuitable for participation in the study based on the Investigator's assessment
Resting heart rate greater than or equal to 100 beats per minute (BPM) after 5 minutes rest (as above) at the screening visit
QTcF interval (Fredericia's correction factor) greater than 450 msec (males subjects) at screening
History of drug or other allergy, which, in the opinion of the Investigator, contraindicates their participation
History of smoking, including e-cigarettes, within 3 months of the study and/or a positive urine cotinine at screening
Regular alcohol consumption averaging ≥ 14 drinks/week for men (1 drink = 5 ounces of wine or 12 ounces of beer or 1.5 ounces of hard liquor) within 6 months of the first dose of study medication.
Positive urine drug or alcohol test at screening
Any other condition and/or situation that causes the Investigator to deem a subject unsuitable for the study (e.g., due to expected study medication non-compliance, inability to medically tolerate the study procedures, or a subject's unwillingness to comply with study-related procedures)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Eliot Ohlstein, PhD
Organizational Affiliation
Velicept Therapeutics, Inc.
Official's Role
Study Director
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Evaluate the Safety, Tolerability and PK of Different Formulations of Orally Administered Solabegron in Healthy Male Subjects
We'll reach out to this number within 24 hrs